Cetrorelix at the ACR 2012 in Washington

Cetrorelix is a gonadotropin-releasing hormone antagonist (GnRH antagonist). I expected some new results. Older results here: http://rheumatologe.blogspot.de/2012/07/cetrorelix-at-eular-2012.html

And there are new results! A. Kass and colleagues looked at cetrorelix in a proof-of concept study and it demonstrates efficacy in patients with active rheumatoid arthritis (Abstract No. 834). Their results showed that “more patients on cetrorelix achieved ACR20 responses (40% vs 18%; p_0.015)”. Nothing that makes drop off your chair, but at least a result to work on. Conclusions included: “Larger, long-term studies on the efficacy and safety of GnRH antagonists in RA patients are warranted.”

No other abstract on cetrorelix! It doesn’t sound like a success story, but it’s interesting enough to be followed. We’ll just have to wait for further results.
19.06.2013
Nothing at the EULAR 2013 Meeting in Madrid.